Across TCGA pan-cancer cohorts, CDC23 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDC23 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CDC23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDC23 expression acts as an unfavorable survival marker.
COAD, LIHC, and PRAD are the cancer types where CDC23 Mutation most reproducibly stratifies survival.